ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global...

from PR Newswire: https://ift.tt/2TT8wGG